Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

VAMP-associated protein-A and oxysterol-binding protein-related protein 3 promote the entry of late endosomes into the nucleoplasmic reticulum.

Santos MF, Rappa G, Karbanova J, Kurth T, Corbeil D, Lorico A.

J Biol Chem. 2018 Jul 17. pii: jbc.RA118.003725. doi: 10.1074/jbc.RA118.003725. [Epub ahead of print]

2.

Investigation on different chemical stability of mitochondrial Hsp60 and its precursor.

Ricci C, Carrotta R, Rappa GC, Mangione MR, Librizzi F, San Biagio PL, Amenitsch H, Ortore MG, Vilasi S.

Biophys Chem. 2017 Oct;229:31-38. doi: 10.1016/j.bpc.2017.07.008. Epub 2017 Jul 26.

PMID:
28774748
3.

Observation-driven inquiry: Raman spectroscopic imaging illuminates cancer lipid metabolism.

Lorico A, Rappa G, Corbeil D, Le TT.

Stem Cell Investig. 2017 May 26;4:42. doi: 10.21037/sci.2017.04.09. eCollection 2017. No abstract available.

4.

The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells.

Chao OS, Chang TC, Di Bella MA, Alessandro R, Anzanello F, Rappa G, Goodman OB, Lorico A.

J Cell Biochem. 2017 Dec;118(12):4414-4424. doi: 10.1002/jcb.26095. Epub 2017 May 31.

PMID:
28452069
5.

Nuclear transport of cancer extracellular vesicle-derived biomaterials through nuclear envelope invagination-associated late endosomes.

Rappa G, Santos MF, Green TM, Karbanová J, Hassler J, Bai Y, Barsky SH, Corbeil D, Lorico A.

Oncotarget. 2017 Feb 28;8(9):14443-14461. doi: 10.18632/oncotarget.14804.

6.
7.

Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype.

Green TM, Alpaugh ML, Barsky SH, Rappa G, Lorico A.

Biomed Res Int. 2015;2015:634865. doi: 10.1155/2015/634865. Epub 2015 Oct 27. Review.

8.

Extracellular vesicle-mediated transfer of CLIC1 protein is a novel mechanism for the regulation of glioblastoma growth.

Setti M, Osti D, Richichi C, Ortensi B, Del Bene M, Fornasari L, Beznoussenko G, Mironov A, Rappa G, Cuomo A, Faretta M, Bonaldi T, Lorico A, Pelicci G.

Oncotarget. 2015 Oct 13;6(31):31413-27. doi: 10.18632/oncotarget.5105.

9.

Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells.

Rappa G, Green TM, Karbanová J, Corbeil D, Lorico A.

Oncotarget. 2015 Apr 10;6(10):7970-91.

10.

Letter to the editor: An intriguing relationship between lipid droplets, cholesterol-binding protein CD133 and Wnt/β-catenin signaling pathway in carcinogenesis.

Rappa G, Fargeas CA, Le TT, Corbeil D, Lorico A.

Stem Cells. 2015 Apr;33(4):1366-70. doi: 10.1002/stem.1953. No abstract available.

11.

The nuclear pool of tetraspanin CD9 contributes to mitotic processes in human breast carcinoma.

Rappa G, Green TM, Lorico A.

Mol Cancer Res. 2014 Dec;12(12):1840-50. doi: 10.1158/1541-7786.MCR-14-0242. Epub 2014 Aug 7.

12.

Biochemical and biological characterization of exosomes containing prominin-1/CD133.

Rappa G, Mercapide J, Anzanello F, Pope RM, Lorico A.

Mol Cancer. 2013 Jun 14;12:62. doi: 10.1186/1476-4598-12-62.

13.

Wnt interaction and extracellular release of prominin-1/CD133 in human malignant melanoma cells.

Rappa G, Mercapide J, Anzanello F, Le TT, Johlfs MG, Fiscus RR, Wilsch-Bräuninger M, Corbeil D, Lorico A.

Exp Cell Res. 2013 Apr 1;319(6):810-9. doi: 10.1016/j.yexcr.2013.01.003. Epub 2013 Jan 12.

14.

Relationship between tumor cell invasiveness and polyploidization.

Mercapide J, Anzanello F, Rappa G, Lorico A.

PLoS One. 2012;7(12):e53364. doi: 10.1371/journal.pone.0053364. Epub 2012 Dec 31.

15.

Prominin-1 (CD133) and Metastatic Melanoma: Current Knowledge and Therapeutic Perspectives.

Lorico A, Mercapide J, Rappa G.

Adv Exp Med Biol. 2013;777:197-211. doi: 10.1007/978-1-4614-5894-4_13.

PMID:
23161084
16.

Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity.

Rappa G, Mercapide J, Lorico A.

Am J Pathol. 2012 Jun;180(6):2504-15. doi: 10.1016/j.ajpath.2012.02.020. Epub 2012 Apr 27.

17.

The intrinsic fusogenicity of glioma cells as a factor of transformation and progression in the tumor microenvironment.

Mercapide J, Rappa G, Lorico A.

Int J Cancer. 2012 Jul 15;131(2):334-43. doi: 10.1002/ijc.26361. Epub 2011 Aug 30.

18.

Phenotypic heterogeneity of breast cancer stem cells.

Lorico A, Rappa G.

J Oncol. 2011;2011:135039. doi: 10.1155/2011/135039. Epub 2011 Jan 17.

19.

Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.

Rappa G, Anzanello F, Lorico A.

Cancer Chemother Pharmacol. 2011 Apr;67(4):919-26. doi: 10.1007/s00280-010-1394-x. Epub 2010 Jul 2.

20.

Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.

Rappa G, Lorico A.

Exp Cell Res. 2010 May 15;316(9):1576-86. doi: 10.1016/j.yexcr.2010.01.012. Epub 2010 Jan 11.

21.

Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma.

Mercapide J, Rappa G, Anzanello F, King J, Fodstad O, Lorico A.

Int J Cancer. 2010 Mar 1;126(5):1206-15. doi: 10.1002/ijc.24809.

22.

The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma.

Rappa G, Fodstad O, Lorico A.

Stem Cells. 2008 Dec;26(12):3008-17. doi: 10.1634/stemcells.2008-0601. Epub 2008 Sep 18.

23.

Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets.

Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J, Fodstad O, Lorico A.

Exp Cell Res. 2008 Jun 10;314(10):2110-22. doi: 10.1016/j.yexcr.2008.03.008. Epub 2008 Mar 20.

24.

Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma.

Lorico A, Mercapide J, Solodushko V, Alexeyev M, Fodstad O, Rappa G.

Cancer Gene Ther. 2008 Sep;15(9):605-15. doi: 10.1038/cgt.2008.23. Epub 2008 Apr 18. Erratum in: Cancer Gene Ther. 2009 Jun;16(6):539. Soloduschko, V [corrected to Solodushko, V].

PMID:
18421309
25.

Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease.

Rappa G, Anzanello F, Alexeyev M, Fodstad O, Lorico A.

Eur J Haematol. 2007 May;78(5):440-8. Epub 2007 Feb 27.

PMID:
17331133
26.

Gamma-glutamylcysteine synthetase and L-buthionine-(S,R)-sulfoximine: a new selection strategy for gene-transduced neural and hematopoietic stem/progenitor cells.

Lorico A, Bratbak D, Meyer J, Kunke D, Krauss S, Plott WE, Solodushko V, Baum C, Fodstad O, Rappa G.

Hum Gene Ther. 2005 Jun;16(6):711-24.

PMID:
15960602
27.

Efficient expansion and gene transduction of mouse neural stem/progenitor cells on recombinant fibronectin.

Rappa G, Kunke D, Holter J, Diep DB, Meyer J, Baum C, Fodstad O, Krauss S, Lorico A.

Neuroscience. 2004;124(4):823-30.

PMID:
15026123
28.

Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells.

Cisternino S, Rousselle C, Lorico A, Rappa G, Scherrmann JM.

Pharm Res. 2003 Jun;20(6):904-9.

PMID:
12817896
29.
30.

Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice.

Lorico A, Bertola A, Baum C, Fodstad O, Rappa G.

Biochem Biophys Res Commun. 2002 Mar 1;291(3):617-22.

PMID:
11855834
31.

Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice.

Lorico A, Nesland J, Emilsen E, Fodstad O, Rappa G.

Toxicology. 2002 Feb 28;171(2-3):201-5.

PMID:
11836025
33.

Erythrocyte membrane ATP binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis.

Abraham EH, Sterling KM, Kim RJ, Salikhova AY, Huffman HB, Crockett MA, Johnston N, Parker HW, Boyle WE Jr, Hartov A, Demidenko E, Efird J, Kahn J, Grubman SA, Jefferson DM, Robson SC, Thakar JH, Lorico A, Rappa G, Sartorelli AC, Okunieff P.

Blood Cells Mol Dis. 2001 Jan-Feb;27(1):165-80.

PMID:
11358378
34.

Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16).

Rappa G, Shyam K, Lorico A, Fodstad O, Sartorelli AC.

Oncol Res. 2000;12(3):113-9.

PMID:
11216669
35.

Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.

Murren JR, DiStasio SA, Lorico A, McKeon A, Zuhowski EG, Egorin MJ, Sartorelli AC, Rappa G.

Cancer J. 2000 Jul-Aug;6(4):256-65.

PMID:
11038146
36.

Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.

Rappa G, Murren JR, Johnson LM, Lorico A, Sartorelli AC.

Anticancer Drug Des. 2000 Apr;15(2):127-34.

PMID:
10901300
37.

New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models.

Rappa G, Finch RA, Sartorelli AC, Lorico A.

Biochem Pharmacol. 1999 Aug 15;58(4):557-62. Review.

PMID:
10413292
38.

Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.

Cory JG, Cory AH, Lorico A, Rappa G, Sartorelli AC.

Anticancer Res. 1997 Sep-Oct;17(5A):3185-93.

PMID:
9413147
39.
40.
41.

Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.

Rappa G, Lorico A, Liu MC, Kruh GD, Cory AH, Cory JG, Sartorelli AC.

Biochem Pharmacol. 1997 Sep 15;54(6):649-55.

PMID:
9310341
42.

Double knockout of the MRP gene leads to increased drug sensitivity in vitro.

Lorico A, Rappa G, Flavell RA, Sartorelli AC.

Cancer Res. 1996 Dec 1;56(23):5351-5.

43.

Multifunctional modulators of drug resistance.

Murren JR, Rappa G, Cheng YC.

Cancer Treat Res. 1996;87:381-408. Review. No abstract available.

PMID:
8886462
44.

Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.

Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF, Sartorelli AC.

Cancer Res. 1995 Oct 1;55(19):4352-60.

45.
46.

Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones.

Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, Sartorelli AC.

Biochem Pharmacol. 1994 Jul 19;48(2):335-44.

PMID:
8053929
47.
48.

Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells.

Lorico A, Rappa G, Sartorelli AC.

Int J Cancer. 1992 Dec 2;52(6):903-9.

PMID:
1334054
49.

Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).

Rappa G, Lorico A, Sartorelli AC.

Int J Cancer. 1992 Jul 9;51(5):780-7.

PMID:
1377186

Supplemental Content

Support Center